Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TARO PHARMACEUTICAL INDUSTRIES LTD.

(TARO)
  Report
Delayed Nyse  -  04:00:02 2023-01-27 pm EST
30.50 USD   -0.33%
01/25HC Wainwright Adjusts Price Target on Taro Pharmaceutical Industries to $35 From $54, Maintains Buy Rating
MT
01/24Taro : Fiscal Q3 Earnings Snapshot
AQ
01/24Taro Provides Results for December 31, 2022
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Taro: Fiscal Q3 Earnings Snapshot

01/24/2023 | 05:52pm EST

HAIFA BAY, Israel (AP) _ Taro Pharmaceutical Industries Ltd. (TARO) on Tuesday reported net income of $7.3 million in its fiscal third quarter.

On a per-share basis, the Haifa Bay, Israel-based company said it had net income of 19 cents.

The drug maker posted revenue of $139.2 million in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TARO at https://www.zacks.com/ap/TARO

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about TARO PHARMACEUTICAL INDUSTRIES LTD.
01/25HC Wainwright Adjusts Price Target on Taro Pharmaceutical Industries to $35 From $54, M..
MT
01/24Taro : Fiscal Q3 Earnings Snapshot
AQ
01/24Taro Provides Results for December 31, 2022
BU
01/24Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Third Quarter and ..
CI
01/19Taro to Release Third Quarter Results on January 24, 2023
BU
01/04Taro Pharmaceutical Industries : Results of Annual Shareholder Meeting - Form 6-K
PU
2022Taro Pharmaceutical Swings to Fiscal Q2 Net Loss as Revenue Declines
MT
2022Taro : Fiscal Q2 Earnings Snapshot
AQ
2022Taro Provides Results for September 30, 2022
BU
2022Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Second Quarter and..
CI
More news
Analyst Recommendations on TARO PHARMACEUTICAL INDUSTRIES LTD.
More recommendations
Financials (USD)
Sales 2023 577 M - -
Net income 2023 27,0 M - -
Net Debt 2023 - - -
P/E ratio 2023 42,4x
Yield 2023 -
Capitalization 1 146 M 1 146 M -
Capi. / Sales 2023 1,99x
EV / Sales 2024
Nbr of Employees 1 455
Free-Float 17,9%
Chart TARO PHARMACEUTICAL INDUSTRIES LTD.
Duration : Period :
Taro Pharmaceutical Industries Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TARO PHARMACEUTICAL INDUSTRIES LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 30,50 $
Average target price 35,00 $
Spread / Average Target 14,8%
EPS Revisions
Managers and Directors
Uday Vijaykumar Baldota Chief Executive Officer & Director
William J. Coote Chief Financial, VP & Accounting Officer
Dilip Shantilal Shanghvi Chairman of the board
Avi Avramoff Vice President & Head-Research & Development
Richard Glaze Vice President & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
TARO PHARMACEUTICAL INDUSTRIES LTD.4.89%1 150
JOHNSON & JOHNSON-4.04%441 560
ELI LILLY AND COMPANY-4.40%330 671
NOVO NORDISK A/S0.14%309 711
ROCHE HOLDING AG-0.52%277 411
MERCK & CO., INC.-3.68%270 958